Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Organon & Co. - SIC # 2840 -
Ticker
Exchange
SIC #
Website
Latest Ticker
OGN
New York
2840
www.organon.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Organon & Co.
Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA
- Jun 23rd, 2026 3:30 am
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
- Jun 22nd, 2026 7:00 am
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
- Jun 22nd, 2026 5:30 am
Arletta Pharma Solutions Appoints Steve van Os, MD, as Chief Medical Officer
- Jun 19th, 2026 1:53 am
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada
- Jun 18th, 2026 4:00 am
Is TOFIDENCE’s Expanded CRS and COVID Label Altering The Investment Case For Organon (OGN)?
- Jun 15th, 2026 6:17 pm
Organon (OGN) Stock After New TOFIDENCE Approval A Fresh Look At Valuation And Recovery Potential
- Jun 15th, 2026 2:08 am
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19
- Jun 12th, 2026 7:15 am
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
- Jun 10th, 2026 5:30 am
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
- Jun 9th, 2026 7:00 am
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
- May 29th, 2026 7:00 am
Organon Audit Cleared And New Data Put Valuation And Risks In Focus
- May 25th, 2026 5:08 pm
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia
- May 21st, 2026 3:06 am
Organon to Present New Research on Access and Value at ISPOR 2026
- May 15th, 2026 5:30 am
India’s pharma industry is going global. But can it catch up to China?
- May 13th, 2026 3:00 am
Organon Buyout By Sun Pharma Shifts Focus To Cash Value And Timing
- May 7th, 2026 6:12 am
Lilly, Gilead lead pharma’s M&A boom
- May 7th, 2026 2:52 am
Organon (OGN)’s Investors React Strongly as Sun Pharma Bets Big on Specialty Drug Expansion
- May 1st, 2026 8:46 am
Organon (NYSE:OGN) Misses Q1 CY2026 Revenue Estimates
- Apr 30th, 2026 4:10 pm
Jim Cramer Says “Organon’s Done” Upon a Caller’s Inquiry
- Apr 30th, 2026 1:18 pm
Scroll